Still on very undemanding valuation and looking very well-positioned for growth with the move to favour on onshore suppliers to avoid shipping issues.
Not to mention likely resumption of sales with the spread of Omicron - assuming there'll be a strong demand for medicines which treat the cold/flu like symptoms.
Thoughts?
Add to My Watchlist
What is My Watchlist?